| Website | taligentherapeuti... |
| Category | BioTech |
| Phone | 617-444-8443 |
| Employees | |
| Founded | 2004 |
| Description | Treatment of Inflammatory diseases |
| Series B, 1/08 Sanderling Ventures Alta Partners Clarus Ventures High Country Venture | $65M |
Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company’s lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen’s founders have validated as an important amplification loop in the inflammation process.
